Journal of Clinical Oncology, Vol 20, Issue 16
(August), 2002: 3404-3412
© 2002 American Society for Clinical Oncology
Molecular Detection of Cytokeratin-19Positive Cells in the Peripheral Blood of Patients With Operable Breast Cancer: Evaluation of Their Prognostic Significance
By A. Stathopoulou,
I. Vlachonikolis,
D. Mavroudis,
M. Perraki,
Ch. Kouroussis,
S. Apostolaki,
N. Malamos,
S. Kakolyris,
A. Kotsakis,
N. Xenidis,
D. Reppa,
V. Georgoulias
From the Laboratory of Tumor Cell Biology and Department of Biostatistics, School of Medicine, University of Crete, and Department of Medical Oncology, University General Hospital of Heraklion, Heraklion; and Medical Oncology Unit, Elena Venizelou Hospital, Athens, Greece.
Address reprint requests to Vassilis Georgoulias, MD, PhD, Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, 711 10 Heraklion, Crete, Greece; email: georgoul{at}med.uoc.gr
PURPOSE: To evaluate the prognostic significance of molecular detection of cytokeratin 19 (CK-19) mRNA-positive cells by nested reverse transcriptase polymerase chain reaction (RT-PCR) in the peripheral blood of women with stages I and II breast cancer before adjuvant chemotherapy.
PATIENTS AND METHODS: The sensitivity and specificity of CK-19 mRNA detection by nested RT-PCR were investigated using MCF-7 and ARH-77 cells and blood from healthy women and patients with hematologic malignancies, metastatic colorectal cancer, and early and metastatic breast cancer. Peripheral blood from 148 patients with operable breast cancer, obtained before initiation of any adjuvant therapy, was tested for the presence of CK-19 mRNA-positive cells.
RESULTS: The nested RT-PCR assay for CK-19 mRNA detected one MCF-7 tumor cell in 106 normal peripheral blood mononuclear cells in four of five experiments; no signal was detected with the CK-19negative ARH-77 cells. CK-19 mRNA was detected in the peripheral blood of 3.7% of healthy blood donors, 14.3% of patients with hematologic malignancies, and 3.2% of patients with metastatic colorectal cancer. Detection rates for CK-19 mRNA-positive cells in the bone marrow/blood of patients with early or metastatic breast cancer were 63%/30% and 74%/52%, respectively. For stages I and II breast cancer, detection of CK-19positive cells in the peripheral blood before adjuvant therapy was associated with reduced disease-free interval (P = .0007) and overall survival (P = .01). In multivariate analysis, detection of peripheral-blood CK-19positive cells was an independent prognostic factor for disease relapse and death.
CONCLUSION: Molecular detection of CK-19 mRNA-positive cells by RT-PCR in the peripheral blood of patients with stages I and II breast cancer before initiation of adjuvant therapy has independent prognostic value as a marker of poor clinical outcome.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
N. Xenidis, M. Ignatiadis, S. Apostolaki, M. Perraki, K. Kalbakis, S. Agelaki, E. N. Stathopoulos, G. Chlouverakis, E. Lianidou, S. Kakolyris, et al.
Cytokeratin-19 mRNA-Positive Circulating Tumor Cells After Adjuvant Chemotherapy in Patients With Early Breast Cancer
J. Clin. Oncol.,
May 1, 2009;
27(13):
2177 - 2184.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. F. Hayes and J. Smerage
Is There a Role for Circulating Tumor Cells in the Management of Breast Cancer?
Clin. Cancer Res.,
June 15, 2008;
14(12):
3646 - 3650.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Ignatiadis, G. Kallergi, M. Ntoulia, M. Perraki, S. Apostolaki, M. Kafousi, G. Chlouverakis, E. Stathopoulos, E. Lianidou, V. Georgoulias, et al.
Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast Cancer
Clin. Cancer Res.,
May 1, 2008;
14(9):
2593 - 2600.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Ignatiadis, N. Xenidis, M. Perraki, S. Apostolaki, E. Politaki, M. Kafousi, E. N. Stathopoulos, A. Stathopoulou, E. Lianidou, G. Chlouverakis, et al.
Different Prognostic Value of Cytokeratin-19 mRNA Positive Circulating Tumor Cells According to Estrogen Receptor and HER2 Status in Early-Stage Breast Cancer
J. Clin. Oncol.,
November 20, 2007;
25(33):
5194 - 5202.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Xenidis, V. Markos, S. Apostolaki, M. Perraki, A. Pallis, G. Sfakiotaki, D. Papadatos-Pastos, L. Kalmanti, M. Kafousi, E. Stathopoulos, et al.
Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer
Ann. Onc.,
October 1, 2007;
18(10):
1623 - 1631.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S Apostolaki, M Perraki, A Pallis, V Bozionelou, S Agelaki, P Kanellou, A Kotsakis, E Politaki, K Kalbakis, A Kalykaki, et al.
Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance
Ann. Onc.,
May 1, 2007;
18(5):
851 - 858.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Lacroix
Significance, detection and markers of disseminated breast cancer cells
Endocr. Relat. Cancer,
December 1, 2006;
13(4):
1033 - 1067.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. V. Kumar, G. J. Hurteau, and S. D. Spivack
Validity of Messenger RNA Expression Analyses of Human Saliva
Clin. Cancer Res.,
September 1, 2006;
12(17):
5033 - 5039.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Xenidis, M. Perraki, M. Kafousi, S. Apostolaki, I. Bolonaki, A. Stathopoulou, K. Kalbakis, N. Androulakis, C. Kouroussis, T. Pallis, et al.
Predictive and Prognostic Value of Peripheral Blood Cytokeratin-19 mRNA-Positive Cells Detected by Real-Time Polymerase Chain Reaction in Node-Negative Breast Cancer Patients
J. Clin. Oncol.,
August 10, 2006;
24(23):
3756 - 3762.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Quintela-Fandino, J. M. Lopez, R. Hitt, S. Gamarra, A. Jimeno, R. Ayala, J. Hornedo, C. Guzman, F. Gilsanz, and H. Cortes-Funes
Breast Cancer-Specific mRNA Transcripts Presence in Peripheral Blood After Adjuvant Chemotherapy Predicts Poor Survival Among High-Risk Breast Cancer Patients Treated With High-Dose Chemotherapy With Peripheral Blood Stem Cell Support
J. Clin. Oncol.,
August 1, 2006;
24(22):
3611 - 3618.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Wulfing, J. Borchard, H. Buerger, S. Heidl, K. S. Zanker, L. Kiesel, and B. Brandt
HER2-Positive Circulating Tumor Cells Indicate Poor Clinical Outcome in Stage I to III Breast Cancer Patients.
Clin. Cancer Res.,
March 15, 2006;
12(6):
1715 - 1720.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S Abdul-Rasool, S H Kidson, E Panieri, D Dent, K Pillay, and G S Hanekom
An evaluation of molecular markers for improved detection of breast cancer metastases in sentinel nodes.
J. Clin. Pathol.,
March 1, 2006;
59(3):
289 - 297.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Mercatali, V. Valenti, D. Calistri, S. Calpona, G. Rosti, S. Folli, M. Gaudio, G. L. Frassineti, D. Amadori, and E. Flamini
RT-PCR determination of maspin and mammaglobin B in peripheral blood of healthy donors and breast cancer patients
Ann. Onc.,
March 1, 2006;
17(3):
424 - 428.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Giribaldi, S. Procida, D. Ulliers, F. Mannu, R. Volpatto, G. Mandili, L. Fanchini, O. Bertetto, G. Fronda, L. Simula, et al.
Specific Detection of Cytokeratin 20-Positive Cells in Blood of Colorectal and Breast Cancer Patients by a High Sensitivity Real-Time Reverse Transcriptase-Polymerase Chain Reaction Method
J. Mol. Diagn.,
February 1, 2006;
8(1):
105 - 112.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Stathopoulos
Reply to the Letter to the Editor "Limitations of molecular detection of CK19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically negative axillary lymph nodes" by V. Pitini et al. (Ann Oncol 2005; 16: 1845)
Ann. Onc.,
November 1, 2005;
16(11):
1845 - 1846.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Shinozaki, D. S.B. Hoon, A. E. Giuliano, N. M. Hansen, H.-J. Wang, R. Turner, and B. Taback
Distinct Hypermethylation Profile of Primary Breast Cancer Is Associated with Sentinel Lymph Node Metastasis
Clin. Cancer Res.,
March 15, 2005;
11(6):
2156 - 2162.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Braun and B. Naume
Circulating and Disseminated Tumor Cells
J. Clin. Oncol.,
March 10, 2005;
23(8):
1623 - 1626.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. N. Stathopoulos, E. Sanidas, M. Kafousi, D. Mavroudis, J. Askoxylakis, V. Bozionelou, M. Perraki, D. Tsiftsis, and V. Georgoulias
Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes
Ann. Onc.,
February 1, 2005;
16(2):
240 - 246.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Bozionellou, D. Mavroudis, M. Perraki, S. Papadopoulos, S. Apostolaki, E. Stathopoulos, A. Stathopoulou, E. Lianidou, and V. Georgoulias
Trastuzumab Administration Can Effectively Target Chemotherapy-Resistant Cytokeratin-19 Messenger RNA-Positive Tumor Cells in the Peripheral Blood and Bone Marrow of Patients With Breast Cancer
Clin. Cancer Res.,
December 15, 2004;
10(24):
8185 - 8194.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A M Gilbey, D Burnett, R E Coleman, and I Holen
The detection of circulating breast cancer cells in blood
J. Clin. Pathol.,
September 1, 2004;
57(9):
903 - 911.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-Y. Pierga, C. Bonneton, A. Vincent-Salomon, P. de Cremoux, C. Nos, N. Blin, P. Pouillart, J.-P. Thiery, and H. Magdelenat
Clinical Significance of Immunocytochemical Detection of Tumor Cells Using Digital Microscopy in Peripheral Blood and Bone Marrow of Breast Cancer Patients
Clin. Cancer Res.,
February 15, 2004;
10(4):
1392 - 1400.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Pantel, V. Muller, M. Auer, N. Nusser, N. Harbeck, and S. Braun
Detection and Clinical Implications of Early Systemic Tumor Cell Dissemination in Breast Cancer
Clin. Cancer Res.,
December 15, 2003;
9(17):
6326 - 6334.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Stathopoulou, A. Gizi, M. Perraki, S. Apostolaki, N. Malamos, D. Mavroudis, V. Georgoulias, and E. S. Lianidou
Real-Time Quantification of CK-19 mRNA-Positive Cells in Peripheral Blood of Breast Cancer Patients Using the Lightcycler System
Clin. Cancer Res.,
November 1, 2003;
9(14):
5145 - 5151.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Ismail, W. Wynendaele, J. L. E. Aerts, R. Paridaens, L. Van Mellaert, J. Anne, R. Gaafar, N. Shakankiry, H. M. Khaled, M. R. Christiaens, et al.
Real-time quantitative RT-PCR and detection of tumour cell dissemination in breast cancer patients: plasmid versus cell line dilutions
Ann. Onc.,
August 1, 2003;
14(8):
1241 - 1245.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Xenidis, I. Vlachonikolis, D. Mavroudis, M. Perraki, A. Stathopoulou, N. Malamos, C. Kouroussis, S. Kakolyris, S. Apostolaki, N. Vardakis, et al.
Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer
Ann. Onc.,
June 1, 2003;
14(6):
849 - 855.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|